22468 Results

People

  1. Ladanyi
    Ladanyi
  2. Antonescu
    Antonescu
  3. Offit
    Offit
  4. Solit
    Solit
  5. Levine
    Levine
  6. Berger
    Berger
  7. O'Reilly
    O'Reilly
  8. Cheung
    Cheung
  9. Reis-Filho
    Reis-Filho
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)
  7. Human Oncology and Pathogenesis Program (5697)
  8. Center for Hematologic Malignancies (5359)
  9. Center for Molecular Imaging and Biotechnology (5298)
  10. Department of Pathology and Laboratory Medicine (4773)
  1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Next-generation sequencing of FFPE solid tumor specimens for clinical use
    Meeting Abstract

    Yelensky, R.; Wang, K.; Dogan, S.; Borsu, L.; Frampton, G.; Lipson, D.; Stephens, P.; Bastian, B.; Klimstra, D.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comparison of the KRAS/EGFR mutation profile and survival of "collegiate smokers" and never smokers with advanced lung cancers
    Meeting Abstract

    Varghese, A. M.; Sima, C. S.; Chaft, J. E.; Johnson, M. L.; Janjigian, Y. Y.; Drilon, A. E. D.; Yu, H. A.; Riely, G. J.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Genetic determinants of long-term response to rapalog therapy in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Hakimi, A. A.; Scott, S. N.; Takeda, S.; Liu, H.; Chen, Y.; Motzer, R. J.; Berger, M. F.; Hsieh, J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study
    Meeting Abstract

    Thomas, L.; Wolchok, J. D.; Garbe, C.; Lebbe, C.; Bondarenko, I.; Rodrigues, K.; Konto, C.; Chin, K. M.; Francis, S.; Robert, C.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience
    Meeting Abstract

    Varella-Garcia, M.; Berry, L. D.; Su, P. F.; Franklin, W. A.; Iafrate, A. J.; Ladanyi, M.; Camidge, D. R.; Garon, E. B.; Haura, E. B.; Horn, L.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • KIF5B-RET: Discovery of a novel fusion oncogene in lung adenocarcinomas by a systematic screen for tyrosine kinase fusions and identification of patients for a RET targeted therapy trial
    Meeting Abstract

    Suehara, Y.; Arcila, M. E.; Drilon, A. E. D.; Ito, T.; Wang, L.; Hasanovic, A.; Khanin, R.; Rizvi, N. A.; Ladanyi, M.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Fury, M. G.; Baxi, S. S.; Haque, S.; Korte, S. H.; Smith-Marrone, S.; Xiao, H.; Ghossein, R. A.; Fagin, J. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR plus T cells
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Olszewska, M.; Taylor, C.; Bartido, S.; Scher, H. I.; Sadelain, M.; Riviere, I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS)
    Meeting Abstract

    Schwartz, G. K.; Tap, W. D.; Qin, L. X.; Livingston, M. B.; Undevia, S. D.; Chmielowski, B.; Agulnik, M.; Schuetze, S.; Reed, D. R.; Okuno, S. H.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save